Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its business update and financial results for its fiscal 2023 second quarter ended September 30, 2022, before market open on Monday, November 14, 2022.
The Company will conduct a conference call and webcast to discuss its results that morning, Monday, November 14, 2022, at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13734045. A live webcast of the conference call can be accessed via the Events and Presentations section of the Reunion Investor Relations website here.
For those unable to attend the live call, a telephonic replay will be available until 11:59 p.m. ET on Monday, November 21, 2022. To access the replay dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide conference ID 13734045. The webcast will be archived and available in the Events and Presentations section of the Reunion Investor Relations website approximately one hour after the conclusion of the live call.
About Reunion Neuroscience Inc
Reunion (formerly, Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.